Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 2/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.40 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.39 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.39 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.39 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.39 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.39 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.37 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4072865 | 0.99 | OPRK1 (0.40) | OPRK1OPRM1OPRD1ROCK2ROCK1 | |
| SCHEMBL4083769 | 0.91 | OPRM1 (0.42) | OPRK1OPRM1OPRD1ROCK2ROCK1 | |
| SCHEMBL4079230 | 0.88 | OPRM1 (0.40) | OPRK1OPRM1OPRD1ROCK2ROCK1 | |
| SCHEMBL4073644 | 0.84 | OPRM1 (0.53) | OPRK1OPRM1OPRD1SMN1; SMN2ITGB1 | |
| Hydrochloric Acid SCHEMBL4073979 | 0.83 | OPRM1 (0.52) | OPRK1OPRM1OPRD1SMN1; SMN2ITGB1 | |
| SCHEMBL4075483 | 0.83 | OPRK1 (0.39) | OPRK1OPRM1OPRD1LMNASMN1; SMN2 | |
| SCHEMBL4080078 | 0.80 | OPRM1 (0.41) | OPRK1OPRM1OPRD1ROCK2ROCK1 | |
| SCHEMBL4074422 | 0.80 | OPRM1 (0.44) | OPRK1OPRM1OPRD1LMNASMN1; SMN2 | |
| SCHEMBL4075641 | 0.79 | OPRM1 (0.52) | OPRK1OPRM1OPRD1LMNASMN1; SMN2 | |
| SCHEMBL4080426 | 0.79 | OPRM1 (0.48) | OPRK1OPRM1OPRD1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7615651-B2 | Diaryl, dipyridinyl and aryl-pyridinyl derivatives and uses thereof | PFIZER INC. (US) | 2009-11-10 | — | — | US | disclosed |
| US-7615651-B2 | Diaryl, dipyridinyl and aryl-pyridinyl derivatives and uses thereof | PFIZER INC. (US) | 2009-11-10 | — | — | US | disclosed |
| US-20080167371-A1 | Diaryl, Dipyridinyl and Aryl-Pyridinyl Derivatives and Uses Thereof | PFIZER INC. | 2008-07-10 | — | — | US | disclosed |
| US-20080167371-A1 | Diaryl, Dipyridinyl and Aryl-Pyridinyl Derivatives and Uses Thereof | PFIZER INC. | 2008-07-10 | — | — | US | disclosed |
| WO-2008059335-A1 | DIARYL, DIPYRIDINYL AND ARYL-PYRIDINYL DERIVATIVES AND USES THEREOF | PFIZER PRODUCTS INC. (US) | 2008-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167371-A1 | Diaryl, Dipyridinyl and Aryl-Pyridinyl Derivatives and Uses Thereof | OPRD1, OPRK1, OPRL1 | OPRK1 2/4885OPRM1 4/4885OPRD1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.